$XBIO
Xenetic Biosciences, Inc.

2023 Q2 Form 10-Q Financial Statement

#000168316823003201 Filed on May 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $651.0K $605.8K $389.0K
YoY Change 56.22% 55.75% 104.73%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $946.0K $925.7K $907.3K
YoY Change -7.83% 2.03% -2.44%
% of Gross Profit
Research & Development $903.2K $595.3K $1.101M
YoY Change -56.52% -45.95% 74.83%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.849M $1.521M $2.009M
YoY Change -40.42% -24.28% 28.76%
Operating Profit -$1.198M -$915.2K -$1.620M
YoY Change -55.41% -43.5%
Interest Expense $126.1K $54.10K $25.91K
YoY Change 689.61% 108.8% 29.55%
% of Operating Profit
Other Income/Expense, Net $147.2K $58.62K $200.00
YoY Change 888.82% 29210.5%
Pretax Income -$1.051M -$856.6K -$1.594M
YoY Change -60.67% -46.25% 18.05%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.051M -$856.6K -$1.594M
YoY Change -60.67% -46.25% 18.05%
Net Earnings / Revenue -161.44% -141.38% -409.68%
Basic Earnings Per Share -$0.69 -$0.06 -$0.12
Diluted Earnings Per Share -$0.69 -$0.06 -$118.6K
COMMON SHARES
Basic Shares Outstanding 15.17M shares 15.17M shares 13.44M shares
Diluted Shares Outstanding 1.525M shares 15.17M shares 13.44M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.73M $11.99M $16.16M
YoY Change -28.15% -25.76% 61.4%
Cash & Equivalents $10.73M $11.99M $16.16M
Short-Term Investments
Other Short-Term Assets $1.319M $876.5K $732.4K
YoY Change 193.95% 19.69% -28.9%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $12.04M $12.87M $16.89M
YoY Change -21.67% -23.79% 52.98%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $704.4K $844.4K $1.095M
YoY Change -35.49% -22.87% 49.97%
Total Long-Term Assets $704.4K $844.4K $1.095M
YoY Change -35.49% -22.87% 52.06%
TOTAL ASSETS
Total Short-Term Assets $12.04M $12.87M $16.89M
Total Long-Term Assets $704.4K $844.4K $1.095M
Total Assets $12.75M $13.72M $17.98M
YoY Change -22.58% -23.73% 52.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $221.3K $259.2K $280.7K
YoY Change -53.19% -7.66% 33.66%
Accrued Expenses $650.0K $597.2K $782.6K
YoY Change -19.4% -23.69% 32.64%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $871.3K $856.4K $1.063M
YoY Change -31.89% -19.46% 32.91%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $871.3K $856.4K $1.063M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $871.3K $856.4K $1.063M
YoY Change -31.89% -19.46% 29.67%
SHAREHOLDERS EQUITY
Retained Earnings -$191.0M -$190.0M
YoY Change 2.25%
Common Stock $1.536K $15.19K
YoY Change -89.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $11.88M $12.86M $16.92M
YoY Change
Total Liabilities & Shareholders Equity $12.75M $13.72M $17.98M
YoY Change -22.58% -23.73% 52.92%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$1.051M -$856.6K -$1.594M
YoY Change -60.67% -46.25% 18.05%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.269M -$1.102M -$2.088M
YoY Change 74.11% -47.19% 37.35%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -1.269M -$1.102M -2.088M
Cash From Investing Activities 0.000
Cash From Financing Activities
Net Change In Cash -1.269M -$1.102M -2.088M
YoY Change 3.27% -47.19% 37.35%
FREE CASH FLOW
Cash From Operating Activities -$1.269M -$1.102M -$2.088M
Capital Expenditures $0.00
Free Cash Flow -$1.269M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001534525
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 xbio Exercise Of Purchase Warrants Value
ExerciseOfPurchaseWarrantsValue
usd
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-37937
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
XENETIC BIOSCIENCES, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-2952962
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
945 Concord Street
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Framingham
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01701
CY2023Q1 dei City Area Code
CityAreaCode
781
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
778-7720
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
15166596 shares
CY2023Q1 us-gaap Cash
Cash
11994827 usd
CY2022Q4 us-gaap Cash
Cash
13097265 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
876539 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
556094 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
12871366 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
13653359 usd
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
844431 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1066931 usd
CY2023Q1 us-gaap Assets
Assets
13715797 usd
CY2022Q4 us-gaap Assets
Assets
14720290 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
259180 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
287360 usd
CY2023Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
597185 usd
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
785796 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
856365 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1073156 usd
CY2023Q1 us-gaap Liabilities
Liabilities
856365 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1073156 usd
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15193587 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15193587 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15166596 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15166596 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
15192 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
15192 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
207825084 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
207756232 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-189956172 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-189099618 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
253734 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
253734 usd
CY2023Q1 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
5281180 usd
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
5281180 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
12859432 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
13647134 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13715797 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14720290 usd
CY2023Q1 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
605844 usd
CY2022Q1 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
388993 usd
CY2023Q1 us-gaap Revenues
Revenues
605844 usd
CY2022Q1 us-gaap Revenues
Revenues
388993 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
595276 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1101399 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
925743 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
907309 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
1521019 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
2008708 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-915175 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1619715 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4520 usd
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
199 usd
CY2023Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
54101 usd
CY2022Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
25905 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
58621 usd
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
26104 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-856554 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1593611 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15166596 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15166596 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13440057 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13440057 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
13647134 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
68852 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-856554 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
12859432 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
18394257 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
119595 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1593611 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
16920241 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-856554 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1593611 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
0 usd
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
9475 usd
CY2023Q1 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
68852 usd
CY2022Q1 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
119595 usd
CY2023Q1 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
320445 usd
CY2022Q1 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
262444 usd
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-222500 usd
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
2871 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-216791 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-357835 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1102438 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2087691 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1102438 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2087691 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13097265 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18244030 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11994827 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16156339 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2023Q1 xbio Issuance Of Common Stock From Cashless Exercise Of Purchase Warrants
IssuanceOfCommonStockFromCashlessExerciseOfPurchaseWarrants
0 usd
CY2022Q1 xbio Issuance Of Common Stock From Cashless Exercise Of Purchase Warrants
IssuanceOfCommonStockFromCashlessExerciseOfPurchaseWarrants
2 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000 usd
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
68852 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
119595 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000 usd
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
38700000 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
38600000 usd
CY2023Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
0 usd
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
9475 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0 usd
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
17568 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0 usd
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
17568 usd

Files In Submission

Name View Source Status
0001683168-23-003201-index-headers.html Edgar Link pending
0001683168-23-003201-index.html Edgar Link pending
0001683168-23-003201.txt Edgar Link pending
0001683168-23-003201-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xbio-20230331.xsd Edgar Link pending
xenetic_ex1001.htm Edgar Link pending
xenetic_ex3101.htm Edgar Link pending
xenetic_ex3102.htm Edgar Link pending
xenetic_ex3201.htm Edgar Link pending
xenetic_i10q-033123.htm Edgar Link pending
xbio-20230331_cal.xml Edgar Link unprocessable
xbio-20230331_def.xml Edgar Link unprocessable
xbio-20230331_lab.xml Edgar Link unprocessable
xbio-20230331_pre.xml Edgar Link unprocessable
xenetic_i10q-033123_htm.xml Edgar Link completed